Benjamin Péant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Benjamin Péant has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Marie Mes-Masson
Centre de recherche du Centre Hospitalier de l’Université de Montréal, Montréal, Canada
15 shared publications - Cécile Le Page
CRCHUM, Montreal, Canada
9 shared publications Nathalie Delvoye
Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM)/Institut du Cancer de Montréal, Montreal, Canada
7 shared publicationsFred Saad
Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM)/Institut du Cancer de Montréal, Montreal, Canada
5 shared publications- Jean-Simon Diallo
Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada
5 shared publications - Fred Saad
University of Montreal
4 shared publications
Latest Publications
- Open Access
A marine worm oxygen carrier to improve the quality of preserved tumor samples
Biobanked tissue samples are essential for cancer research, yet pre-analytical ischemia-hypoxia during tissue handling can compromise tissue or derived models quality, limiting their value for translational research. Here, we investigated whether M101, an extracellular hemoglobin from Arenicola marina, could mitigate, indirectly by providing oxygen, handling-induced ischemia-hypoxia in cancer tissues and subsequent live 3D models. Using prostate cancer PC3 and ovarian cancer TOV-21G XG preserved ex vivo, M101 reduced the emergence of hypoxia-associated markers, including the hypoxia-inducible factor 1-alpha, and attenuated metabolic stress. In XG-derived micro-dissected 3D tumor models cultured for 8 days, M101 improved tissue morphology, reduced fragmentation, and was associated with higher proliferative activity and lower inflammatory interleukin-6 release. Together, these findings suggest that M101 helps preserve structural and functional features of biobanked tumor models during ex vivo handling. Thus, oxygen carriers could represent a bio-compatible strategy to improve the fidelity of biobanked samples and patient-derived tumor models for precision oncology applications.
Open AccessA marine worm oxygen carrier to improve the quality of preserved tumor samples
Biobanked tissue samples are essential for cancer research, yet pre-analytical ischemia-hypoxia during tissue handling can compromise tissue or derived models quality, limiting their value for translational research. Here, we investigated whether M101, an extracellular hemoglobin from Arenicola marina, could mitigate, indirectly by providing oxygen, handling-induced ischemia-hypoxia in cancer tissues and subsequent live 3D models. Using prostate cancer PC3 and ovarian cancer TOV-21G XG preserved ex vivo, M101 reduced the emergence of hypoxia-associated markers, including the hypoxia-inducible factor 1-alpha, and attenuated metabolic stress. In XG-derived micro-dissected 3D tumor models cultured for 8 days, M101 improved tissue morphology, reduced fragmentation, and was associated with higher proliferative activity and lower inflammatory interleukin-6 release. Together, these findings suggest that M101 helps preserve structural and functional features of biobanked tumor models during ex vivo handling. Thus, oxygen carriers could represent a bio-compatible strategy to improve the fidelity of biobanked samples and patient-derived tumor models for precision oncology applications.
- 1 April 2019
- Published by Oxford University Press (OUP) in Integrative Biology
- Vol. 11 (4) , 130-141
Long-term fluorescence hyperspectral imaging of on-chip treated co-culture tumour spheroids to follow clonal evolution
Multicellular tumour spheroids are an ideal in vitro tumour model to study clonal heterogeneity and drug resistance in cancer research because different cell types can be mixed at will. However, measuring the individual response of each cell population over time is challenging: current methods are either destructive, such as flow cytometry, or cannot image throughout a spheroid, such as confocal microscopy. Our group previously developed a wide-field fluorescence hyperspectral imaging system to study spheroids formed and cultured in microfluidic chips. In the present study, two subclones of a single parental ovarian cancer cell line transfected to express different fluorophores were produced and co-culture spheroids were formed on-chip using ratios forming highly asymmetric subpopulations. We performed a 3D proliferation assay on each cell population forming the spheroids that matched the 2D growth behaviour. Response assays to PARP inhibitors and platinum-based drugs were also performed to follow the clonal evolution of mixed populations. Our experiments show that hyperspectral imaging can detect spheroid response before observing a decrease in spheroid diameter. Hyperspectral imaging and microfluidic-based spheroid assays provide a versatile solution to study clonal heterogeneity, able to measure response in subpopulations presenting as little as 10% of the initial spheroid.
- 1 April 2019
- Published by Oxford University Press (OUP) in Integrative Biology
- Vol. 11 (4) , 130-141
Long-term fluorescence hyperspectral imaging of on-chip treated co-culture tumour spheroids to follow clonal evolution
Multicellular tumour spheroids are an ideal in vitro tumour model to study clonal heterogeneity and drug resistance in cancer research because different cell types can be mixed at will. However, measuring the individual response of each cell population over time is challenging: current methods are either destructive, such as flow cytometry, or cannot image throughout a spheroid, such as confocal microscopy. Our group previously developed a wide-field fluorescence hyperspectral imaging system to study spheroids formed and cultured in microfluidic chips. In the present study, two subclones of a single parental ovarian cancer cell line transfected to express different fluorophores were produced and co-culture spheroids were formed on-chip using ratios forming highly asymmetric subpopulations. We performed a 3D proliferation assay on each cell population forming the spheroids that matched the 2D growth behaviour. Response assays to PARP inhibitors and platinum-based drugs were also performed to follow the clonal evolution of mixed populations. Our experiments show that hyperspectral imaging can detect spheroid response before observing a decrease in spheroid diameter. Hyperspectral imaging and microfluidic-based spheroid assays provide a versatile solution to study clonal heterogeneity, able to measure response in subpopulations presenting as little as 10% of the initial spheroid.
- 10 January 2019
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 19 (4) , 693-705
Paraffin-embedding lithography and micro-dissected tissue micro-arrays: tools for biological and pharmacological analysis of ex vivo solid tumors
There is an urgent need and strong clinical and pharmaceutical interest in developing assays that allow for the direct testing of therapeutic agents on primary tissues. Current technologies fail to provide the required sample longevity, throughput, and integration with standard clinically proven assays to make the approach viable. Here we report a microfluidic micro-histological platform that enables ex vivo culture of a large array of prostate and ovarian cancer micro-dissected tissue (MDT) followed by direct on-chip fixation and paraffination, a process we term paraffin-embedding lithography (PEL). The result is a high density MDT-Micro Array (MDTMA) compatible with standard clinical histopathology that can be used to analyse ex vivo tumor response or resistance to therapeutic agents. The cellular morphology and tissue architecture are preserved in MDTs throughout the 15 day culture period. We also demonstrate how this methodology can be used to study molecular pathways involved in cancer by performing in-depth characterization of biological and pharmacological mechanisms such as p65 nuclear translocation via TNF stimuli, and to predict the treatment outcome in the clinic via MDT response to taxane-based therapies.
- 10 January 2019
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 19 (4) , 693-705
Paraffin-embedding lithography and micro-dissected tissue micro-arrays: tools for biological and pharmacological analysis of ex vivo solid tumors
There is an urgent need and strong clinical and pharmaceutical interest in developing assays that allow for the direct testing of therapeutic agents on primary tissues. Current technologies fail to provide the required sample longevity, throughput, and integration with standard clinically proven assays to make the approach viable. Here we report a microfluidic micro-histological platform that enables ex vivo culture of a large array of prostate and ovarian cancer micro-dissected tissue (MDT) followed by direct on-chip fixation and paraffination, a process we term paraffin-embedding lithography (PEL). The result is a high density MDT-Micro Array (MDTMA) compatible with standard clinical histopathology that can be used to analyse ex vivo tumor response or resistance to therapeutic agents. The cellular morphology and tissue architecture are preserved in MDTs throughout the 15 day culture period. We also demonstrate how this methodology can be used to study molecular pathways involved in cancer by performing in-depth characterization of biological and pharmacological mechanisms such as p65 nuclear translocation via TNF stimuli, and to predict the treatment outcome in the clinic via MDT response to taxane-based therapies.
- 12 July 2018
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 143 (16) , 3829-3840
Fluorescence hyperspectral imaging for live monitoring of multiple spheroids in microfluidic chips
Tumor spheroids represent a realistic 3D in vitro cancer model because they provide a missing link between monolayer cell culture and live tissues. While microfluidic chips can easily form and assay thousands of spheroids simultaneously, few commercial instruments are available to analyze this massive amount of data. Available techniques to measure spheroid response to external stimuli, such as confocal imaging and flow cytometry, are either not appropriate for 3D cultures, or destructive. We designed a wide-field hyperspectral imaging system to analyze multiple spheroids trapped in a microfluidic chip in a single acquisition. The system and its fluorescence quantification algorithm were assessed using liquid phantoms mimicking spheroid optical properties. Spectral unmixing was tested on three overlapping spectral entities. Hyperspectral images of co-culture spheroids expressing two fluorophores were compared with confocal microscopy and spheroid growth was measured over time. The system can spectrally analyze multiple fluorescent markers simultaneously and allows multiple time-points assays, providing a fast and versatile solution for analyzing lab on a chip devices.
- 12 July 2018
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 143 (16) , 3829-3840
Fluorescence hyperspectral imaging for live monitoring of multiple spheroids in microfluidic chips
Tumor spheroids represent a realistic 3D in vitro cancer model because they provide a missing link between monolayer cell culture and live tissues. While microfluidic chips can easily form and assay thousands of spheroids simultaneously, few commercial instruments are available to analyze this massive amount of data. Available techniques to measure spheroid response to external stimuli, such as confocal imaging and flow cytometry, are either not appropriate for 3D cultures, or destructive. We designed a wide-field hyperspectral imaging system to analyze multiple spheroids trapped in a microfluidic chip in a single acquisition. The system and its fluorescence quantification algorithm were assessed using liquid phantoms mimicking spheroid optical properties. Spectral unmixing was tested on three overlapping spectral entities. Hyperspectral images of co-culture spheroids expressing two fluorophores were compared with confocal microscopy and spheroid growth was measured over time. The system can spectrally analyze multiple fluorescent markers simultaneously and allows multiple time-points assays, providing a fast and versatile solution for analyzing lab on a chip devices.
- Open Access
- 26 August 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (9) , 14487-14501
IκB-Kinase-epsilon (IKKε) over-expression promotes the growth of prostate cancer through the C/EBP-β dependent activation of IL-6 gene expression
IκB-Kinase-epsilon (IKKε) over-expression promotes the growth of prostate cancer through the C/EBP-β dependent activation of IL-6 gene expression
- 26 August 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (9) , 14487-14501
Open AccessIκB-Kinase-epsilon (IKKε) over-expression promotes the growth of prostate cancer through the C/EBP-β dependent activation of IL-6 gene expression
IκB-Kinase-epsilon (IKKε) over-expression promotes the growth of prostate cancer through the C/EBP-β dependent activation of IL-6 gene expression
- 2 December 2015
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 16 (2) , 312-325
Micro-dissected tumor tissues on chip: an ex vivo method for drug testing and personalized therapy
Micro-dissected tumor tissues (MDTs) are maintained alive on chip for several days and show promising results for personalized medicine applications.
- 2 December 2015
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 16 (2) , 312-325
Micro-dissected tumor tissues on chip: an ex vivo method for drug testing and personalized therapy
Micro-dissected tumor tissues (MDTs) are maintained alive on chip for several days and show promising results for personalized medicine applications.
- Open Access
- 17 July 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (7) , e0131024
Potential Cross-Talk between Alternative and Classical NF-κB Pathways in Prostate Cancer Tissues as Measured by a Multi-Staining Immunofluorescence Co-Localization Assay
While the classical NF-κB/p65 pathway is known to be involved in prostate cancer progression and is associated with poor patient outcome, the role of the NF-κB /RelB alternative protein is not well defined. Here we analyzed the activation of both NF-κB pathways in prostate cancer tissues and correlate this activation with clinical features of the disease. A multiple immunofluorescence technique was employed to concomitantly and quantitatively visualize the nuclear localization of p65 and RelB in 200 paraffin embedded samples. Epithelia were defined using appropriate fluorochrome markers and the resulting immunofluorescent signals were quantified with an automated scoring system. The nuclear frequency of p65 was found to be significantly increased in tumor tissues as compared with normal adjacent tissue, whereas the frequency for RelB was decreased (p < 0.001, Wilcoxon test). As previously reported, p65 nuclear frequency was associated with a risk of biochemical recurrence. Although, RelB nuclear frequency alone did not predict recurrence, the presence of activated RelB reduced the risk of recurrence associated with the activation of p65. For the first time p65/RelB co-distribution was assessed in prostate cancer tissues and suggested a negative crosstalk between the two NF-κB pathways in prostate cancer progression.
- 17 July 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (7) , e0131024
Open AccessPotential Cross-Talk between Alternative and Classical NF-κB Pathways in Prostate Cancer Tissues as Measured by a Multi-Staining Immunofluorescence Co-Localization Assay
While the classical NF-κB/p65 pathway is known to be involved in prostate cancer progression and is associated with poor patient outcome, the role of the NF-κB /RelB alternative protein is not well defined. Here we analyzed the activation of both NF-κB pathways in prostate cancer tissues and correlate this activation with clinical features of the disease. A multiple immunofluorescence technique was employed to concomitantly and quantitatively visualize the nuclear localization of p65 and RelB in 200 paraffin embedded samples. Epithelia were defined using appropriate fluorochrome markers and the resulting immunofluorescent signals were quantified with an automated scoring system. The nuclear frequency of p65 was found to be significantly increased in tumor tissues as compared with normal adjacent tissue, whereas the frequency for RelB was decreased (p < 0.001, Wilcoxon test). As previously reported, p65 nuclear frequency was associated with a risk of biochemical recurrence. Although, RelB nuclear frequency alone did not predict recurrence, the presence of activated RelB reduced the risk of recurrence associated with the activation of p65. For the first time p65/RelB co-distribution was assessed in prostate cancer tissues and suggested a negative crosstalk between the two NF-κB pathways in prostate cancer progression.
- 19 September 2011
- Published by Wiley in The Prostate
- Vol. 72 (7) , 777-788
ErbB2/Her-2 regulates the expression of Akt2 in prostate cancer cells
BACKGROUND We have previously reported that ErbB family members regulate the signaling pathway leading to Akt and NF‐kappaB activation in prostate cancer cells. In this study, the regulation of Akt2 expression in LNCaP, DU145, and PC‐3 prostate cancer cell lines was investigated. METHODS Akt‐2 expression was analyzed by western‐blotting and Q‐PCR in cell lines. We also analyzed the Akt‐2 protein expression in a tissue microarray from 64 prostate cancer patients. Akt‐2 promoter activity was assessed and analyzed by luciferase assay. RESULTS A concomitant over‐expression of Her‐2 and Akt2 expression was observed by western‐blotting and quantitative‐PCR in prostate cancer cell lines. A significant correlation between Her‐2 and Akt2 protein expression was also observed by immunohistochemistry assay on prostate cancer tissues. In LNCaP cells, over‐expression of Akt2 protein and mRNA was decreased by Her‐2 pharmacologic inhibitors as well as small interfering RNA (siRNA) specific to Her‐2. Cloning of the AKT2 promoter in a luciferase reporter plasmid further showed that Akt2 over‐expression in cell lines is associated with increased AKT2 promoter activity suggesting that Her‐2 modulates a signaling pathway involving AKT2 gene regulation. CONCLUSION This study reveals a novel mechanism of Akt2 regulation in prostate cancer cells. Prostate 72:777–788, 2012.
- 19 September 2011
- Published by Wiley in The Prostate
- Vol. 72 (7) , 777-788
ErbB2/Her-2 regulates the expression of Akt2 in prostate cancer cells
BACKGROUND We have previously reported that ErbB family members regulate the signaling pathway leading to Akt and NF‐kappaB activation in prostate cancer cells. In this study, the regulation of Akt2 expression in LNCaP, DU145, and PC‐3 prostate cancer cell lines was investigated. METHODS Akt‐2 expression was analyzed by western‐blotting and Q‐PCR in cell lines. We also analyzed the Akt‐2 protein expression in a tissue microarray from 64 prostate cancer patients. Akt‐2 promoter activity was assessed and analyzed by luciferase assay. RESULTS A concomitant over‐expression of Her‐2 and Akt2 expression was observed by western‐blotting and quantitative‐PCR in prostate cancer cell lines. A significant correlation between Her‐2 and Akt2 protein expression was also observed by immunohistochemistry assay on prostate cancer tissues. In LNCaP cells, over‐expression of Akt2 protein and mRNA was decreased by Her‐2 pharmacologic inhibitors as well as small interfering RNA (siRNA) specific to Her‐2. Cloning of the AKT2 promoter in a luciferase reporter plasmid further showed that Akt2 over‐expression in cell lines is associated with increased AKT2 promoter activity suggesting that Her‐2 modulates a signaling pathway involving AKT2 gene regulation. CONCLUSION This study reveals a novel mechanism of Akt2 regulation in prostate cancer cells. Prostate 72:777–788, 2012.
- 26 January 2011
- Published by Wiley in The Prostate
- Vol. 71 (10) , 1131-1138
IκB‐Kinase‐ε (IKKε/IKKi/IκBKε) expression and localization in prostate cancer tissues
BACKGROUND: Advanced prostate cancer (PCa) remains a one of the leading causes of cancer related death and is often due to the progression from a hormone sensitive (HS) to a castrate resistant (CR) state for which therapeutic alternatives remain palliative. Molecular events involved in the progression to CR‐PCa remain largely unknown. A previous study reported significantly higher levels of Iκ‐B kinase‐epsilon (IKKε) expression in CR compared to androgen‐responsive cell lines. In the present study, we evaluate IKKε expression in human prostate tissue.METHODS: In order to evaluate the modulation of IKKε expression in PCa tissue IKKε immunostaining was performed on paraffin‐embedded prostate tissue microarrays containing cores from normal tissues (n = 47), non‐malignant tissues adjacent to the tumor (n = 53), prostatic intraepithelial neoplasia (PIN) (n = 28), HS (n = 62), and CR tumors (n = 31).RESULTS: We found a low cytoplasmic expression of IKKε in non‐malignant tissue. HS tumors showed a significant increase in cytoplasmic IKKε expression compared to non‐malignant tissues. CR tissues presented the highest cytoplasmic IKKε expression levels. We also report, for the first time, the presence of a nuclear localization of IKKε in prostate epithelial cells, in particular we observed an increase of IKKε nuclear localization in HS malignant tissues. Finally, we found a strong link between an increase of IKKε cytoplasmic expression in PCa and metastatic progression.CONCLUSION: This study strongly suggests the role of IKKε as a PCa oncogene that may be involved in the emergence of a CR state. Prostate 71:1131–1138, 2011.
- 26 January 2011
- Published by Wiley in The Prostate
- Vol. 71 (10) , 1131-1138
IκB‐Kinase‐ε (IKKε/IKKi/IκBKε) expression and localization in prostate cancer tissues
BACKGROUND: Advanced prostate cancer (PCa) remains a one of the leading causes of cancer related death and is often due to the progression from a hormone sensitive (HS) to a castrate resistant (CR) state for which therapeutic alternatives remain palliative. Molecular events involved in the progression to CR‐PCa remain largely unknown. A previous study reported significantly higher levels of Iκ‐B kinase‐epsilon (IKKε) expression in CR compared to androgen‐responsive cell lines. In the present study, we evaluate IKKε expression in human prostate tissue.METHODS: In order to evaluate the modulation of IKKε expression in PCa tissue IKKε immunostaining was performed on paraffin‐embedded prostate tissue microarrays containing cores from normal tissues (n = 47), non‐malignant tissues adjacent to the tumor (n = 53), prostatic intraepithelial neoplasia (PIN) (n = 28), HS (n = 62), and CR tumors (n = 31).RESULTS: We found a low cytoplasmic expression of IKKε in non‐malignant tissue. HS tumors showed a significant increase in cytoplasmic IKKε expression compared to non‐malignant tissues. CR tissues presented the highest cytoplasmic IKKε expression levels. We also report, for the first time, the presence of a nuclear localization of IKKε in prostate epithelial cells, in particular we observed an increase of IKKε nuclear localization in HS malignant tissues. Finally, we found a strong link between an increase of IKKε cytoplasmic expression in PCa and metastatic progression.CONCLUSION: This study strongly suggests the role of IKKε as a PCa oncogene that may be involved in the emergence of a CR state. Prostate 71:1131–1138, 2011.
- Open Access
- 11 August 2010
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (8) , e12107
Androgen-Regulated Expression of Arginase 1, Arginase 2 and Interleukin-8 in Human Prostate Cancer
Prostate cancer (PCa) is the most frequently diagnosed cancer in North American men. Androgen-deprivation therapy (ADT) accentuates the infiltration of immune cells within the prostate. However, the immunosuppressive pathways regulated by androgens in PCa are not well characterized. Arginase 2 (ARG2) expression by PCa cells leads to a reduced activation of tumor-specific T cells. Our hypothesis was that androgens could regulate the expression of ARG2 by PCa cells. In this report, we demonstrate that both ARG1 and ARG2 are expressed by hormone-sensitive (HS) and hormone-refractory (HR) PCa cell lines, with the LNCaP cells having the highest arginase activity. In prostate tissue samples, ARG2 was more expressed in normal and non-malignant prostatic tissues compared to tumor tissues. Following androgen stimulation of LNCaP cells with 10 nM R1881, both ARG1 and ARG2 were overexpressed. The regulation of arginase expression following androgen stimulation was dependent on the androgen receptor (AR), as a siRNA treatment targeting the AR inhibited both ARG1 and ARG2 overexpression. This observation was correlated in vivo in patients by immunohistochemistry. Patients treated by ADT prior to surgery had lower ARG2 expression in both non-malignant and malignant tissues. Furthermore, ARG1 and ARG2 were enzymatically active and their decreased expression by siRNA resulted in reduced overall arginase activity and l-arginine metabolism. The decreased ARG1 and ARG2 expression also translated with diminished LNCaP cells cell growth and increased PBMC activation following exposure to LNCaP cells conditioned media. Finally, we found that interleukin-8 (IL-8) was also upregulated following androgen stimulation and that it directly increased the expression of ARG1 and ARG2 in the absence of androgens. Our data provides the first detailed in vitro and in vivo account of an androgen-regulated immunosuppressive pathway in human PCa through the expression of ARG1, ARG2 and IL-8.
- 11 August 2010
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (8) , e12107
Open AccessAndrogen-Regulated Expression of Arginase 1, Arginase 2 and Interleukin-8 in Human Prostate Cancer
Prostate cancer (PCa) is the most frequently diagnosed cancer in North American men. Androgen-deprivation therapy (ADT) accentuates the infiltration of immune cells within the prostate. However, the immunosuppressive pathways regulated by androgens in PCa are not well characterized. Arginase 2 (ARG2) expression by PCa cells leads to a reduced activation of tumor-specific T cells. Our hypothesis was that androgens could regulate the expression of ARG2 by PCa cells. In this report, we demonstrate that both ARG1 and ARG2 are expressed by hormone-sensitive (HS) and hormone-refractory (HR) PCa cell lines, with the LNCaP cells having the highest arginase activity. In prostate tissue samples, ARG2 was more expressed in normal and non-malignant prostatic tissues compared to tumor tissues. Following androgen stimulation of LNCaP cells with 10 nM R1881, both ARG1 and ARG2 were overexpressed. The regulation of arginase expression following androgen stimulation was dependent on the androgen receptor (AR), as a siRNA treatment targeting the AR inhibited both ARG1 and ARG2 overexpression. This observation was correlated in vivo in patients by immunohistochemistry. Patients treated by ADT prior to surgery had lower ARG2 expression in both non-malignant and malignant tissues. Furthermore, ARG1 and ARG2 were enzymatically active and their decreased expression by siRNA resulted in reduced overall arginase activity and l-arginine metabolism. The decreased ARG1 and ARG2 expression also translated with diminished LNCaP cells cell growth and increased PBMC activation following exposure to LNCaP cells conditioned media. Finally, we found that interleukin-8 (IL-8) was also upregulated following androgen stimulation and that it directly increased the expression of ARG1 and ARG2 in the absence of androgens. Our data provides the first detailed in vitro and in vivo account of an androgen-regulated immunosuppressive pathway in human PCa through the expression of ARG1, ARG2 and IL-8.